Results 11 to 20 of about 2,223,665 (257)

Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma

Computational and Structural Biotechnology Journal, 2023
As sorafenib is a first-line drug for treating advanced hepatocellular carcinoma, sorafenib resistance has historically attracted attention. However, most of this attention has been focused on a series of mechanisms related to drug resistance arising ...
Ruiqi Zheng, Shuang Weng, Jianping Xu, Zhuo Li, Yaru Wang, Zulihumaer Aizimuaji, Sheng Ma, Linlin Zheng, Haiyang Li, Wantao Ying, Weiqi Rong, Ting Xiao   +11 more
doaj   +4 more sources

The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma [PDF]

Frontiers in Oncology, 2021
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death. Sorafenib is approved by the U.S. Food and Drug Administration to be a first-line chemotherapy agent for patients with advanced HCC.
Xinyao Hu, Xinyao Hu, Hua Zhu, Yang Shen, Yang Shen, Xiaoyu Zhang, Xiaoyu Zhang, Xiaoqin He, Xiaoqin He, Ximing Xu, Ximing Xu   +10 more
doaj   +4 more sources

Alcohol induces sorafenib resistance in hepatocellular carcinoma: A translational study. [PDF]

J Mol Med (Berl)
Abstract Background: Alcohol is a major cause of hepatocellular carcinoma (HCC), accounting for 30% of cases worldwide. Sorafenib, a tyrosine kinase inhibitor (TKI), was the standard first-line treatment for advanced HCC until 2021, but sorafenib resistance is common.
Courtois A, Marié C, Fouquet G, Diouf M, Esparteiro D, Ducournau G, Marticho L, Naassila M, Nguyen-Khac E, Marcq I.   +9 more
europepmc   +5 more sources

Microvesicles: the functional mediators in sorafenib resistance

Cancer Drug Resistance, 2022
Overcoming drug resistance in cancer therapies remains challenging, and the tumor microenvironment plays an important part in it. Microvesicles (MVs) are functional natural carriers of cellular information, participate in intercellular communication, and dynamically regulate the tumor microenvironment. They contribute to drug resistance by transferring
He, Cong, Jaffar Ali, Doulathunnisa, Sun, Bo, Sun, Bei-Cheng, Xiao, Zhong-Dang   +4 more
openaire   +3 more sources

Roles and Mechanisms of Ferroptosis in Sorafenib Resistance for Hepatocellular Carcinoma. [PDF]

J Hepatocell Carcinoma
Hepatocellular carcinoma (HCC) is the most prevalent malignant tumor, characterized by a poor prognosis. In recent decades, both the incidence and mortality rates of HCC have risen sharply. Sorafenib has emerged as the first conventional drug approved by the US Food and Drug Administration for first-line treatment in advanced HCC patients due to its ...
Liu R, Cui H, Li D, Guo X, Zhang Z, Tan S, Zhu X.   +6 more
europepmc   +7 more sources

SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma

iScience, 2023
Summary: Drug resistance prominently hampers the effects of systemic therapy of sorafenib to hepatocellular carcinoma (HCC). Epigenetics have critical regulatory roles in drug resistance.
Shanshan Wang, Xin You, Xiaoshu Liu, Fengwei Zhang, Hongjuan Zhou, Xuechai Shang, Long Cai   +6 more
doaj   +2 more sources

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2

Biology, 2023
Sorafenib, a kinase inhibitor, has shown promising therapeutic efficacy in a subset of patients with acute myeloid leukemia (AML). However, despite its clinical effectiveness, sorafenib resistance is frequently observed in clinical settings, and the ...
Xi Xu, Weiwei Ma, Guo Qiu, Li Xuan, Chong He, Tian Zhang, Jian Wang, Qifa Liu   +7 more
doaj   +2 more sources

SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma [PDF]

Neoplasia: An International Journal for Oncology Research, 2014
Hepatocellular carcinoma is the fifth most common solid cancer worldwide. Sorafenib, a small multikinase inhibitor, is the only approved therapy for advanced HCC.
Jung-Chen Su, Ping-Hui Tseng, Szu-Hsien Wu, Cheng-Yi Hsu, Wei-Tien Tai, Yong-Shi Li, I-Ting Chen, Chun-Yu Liu, Kuen-Feng Chen, Chung-Wai Shiau   +9 more
doaj   +2 more sources

Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1

BMC Cancer, 2023
Background Due to the high drug resistance of hepatocellular carcinoma (HCC), sorafenib has limited efficacy in the treatment of advanced HCC. Cancer-associated fibroblasts (CAFs) play an important regulatory role in the induction of chemoresistance ...
Jiali Zhao, En Lin, Zirui Bai, Yingbin Jia, Bo Wang, Yihua Dai, Wenfeng Zhuo, Guifang Zeng, Xialei Liu, Chaonong Cai, Peiping Li, Baojia Zou, Jian Li   +12 more
doaj   +2 more sources

High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo

BMC Cancer, 2017
Background Primary liver cancer is a lethal malignancy with a high mortality worldwide. Currently, sorafenib is the most effective molecular-targeted drug against hepatocellular carcinoma (HCC). However, the sorafenib resistance rate is high.
Yinzong Xiao, Lunquan Sun, Yongming Fu, Yan Huang, Rongrong Zhou, Xingwang Hu, Pengcheng Zhou, Jun Quan, Ning Li, Xue-Gong Fan   +9 more
doaj   +2 more sources